Item 7.01 Regulation FD Disclosure.
On November 22, 2022, VBI Vaccines Inc. (the “Company”) issued a press release
reporting its presentation of additional Phase 1/2a data of VBI-1901 in
recurrent glioblastoma at the 2022 Society for Neuro-Oncology on Friday,
November 18, 2022. A copy of the press release is furnished as Exhibit 99.1 to
this Current Report on Form 8-K and is incorporated by reference herein. The
Company undertakes no obligation to update, supplement or amend the materials
The information in this Current Report on Form 8-K (including Exhibit 99.1
attached hereto) is being furnished pursuant to Item 7.01 and shall not be
deemed to be filed for purposes of Section 18 of the Securities Exchange Act of
1934, as amended (the “Exchange Act”), or otherwise be subject to the
liabilities of that section, nor shall it be deemed to be incorporated by
reference in any filing under the Securities Act of 1933, as amended, or the
Exchange Act, whether made before or after the date hereof and regardless of any
general incorporation language in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits Exhibit No. Description 99.1 Press Release dated November 22, 2022 (furnished pursuant to Item 7.01) 104 Cover Page Interactive Data File (formatted as Inline XBRL)
© Edgar Online, source Glimpses